Mittie K. Doyle

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb et al. · The Lancet · 2013 · 789 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh et al. · Annals of the Rheumatic Diseases · 2014 · 654 citations · Full text

C3 glomerulopathy: consensus report

Matthew C. Pickering, Vivette D. D’Agati, Carla Nester et al. · Kidney International · 2013 · 623 citations · Full text

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Josef S Smolen, Jonathan Kay, Mittie K. Doyle et al. · The Lancet · 2009 · 516 citations

Rheumatoid Disorder, Rheumatology, Autoimmune Disease +11

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

Marco Matucci‐Cerinic, D.E. Furst, Maureen D. Mayes et al. · Annals of the Rheumatic Diseases · 2010 · 489 citations · Full text